156 related articles for article (PubMed ID: 37683536)
1. Selective degradation of BRD4 suppresses lung cancer cell proliferation using GSH-responsive PROTAC precursors.
Fan H; Zhou Z; Yu D; Sun J; Wang L; Jia Y; Tian J; Mi W; Sun H
Bioorg Chem; 2023 Nov; 140():106793. PubMed ID: 37683536
[TBL] [Abstract][Full Text] [Related]
2. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
3. Hydrogen Peroxide-Inducible PROTACs for Targeted Protein Degradation in Cancer Cells.
Yu D; Fan H; Zhou Z; Zhang Y; Sun J; Wang L; Jia Y; Tian J; Campbell A; Mi W; Sun H
Chembiochem; 2023 Sep; 24(17):e202300422. PubMed ID: 37462478
[TBL] [Abstract][Full Text] [Related]
4. Glutathione-Scavenging Nanoparticle-Mediated PROTACs Delivery for Targeted Protein Degradation and Amplified Antitumor Effects.
Liu HJ; Chen W; Wu G; Zhou J; Liu C; Tang Z; Huang X; Gao J; Xiao Y; Kong N; Joshi N; Cao Y; Abdi R; Tao W
Adv Sci (Weinh); 2023 Jun; 10(16):e2207439. PubMed ID: 37066758
[TBL] [Abstract][Full Text] [Related]
5. Versatile Nano-PROTAC-Induced Epigenetic Reader Degradation for Efficient Lung Cancer Therapy.
Zhang HT; Peng R; Chen S; Shen A; Zhao L; Tang W; Wang XH; Li ZY; Zha ZG; Yi M; Zhang L
Adv Sci (Weinh); 2022 Oct; 9(29):e2202039. PubMed ID: 35988145
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras through iRGD Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.
He S; Fang Y; Wu M; Zhang P; Gao F; Hu H; Sheng C; Dong G
J Med Chem; 2023 Dec; 66(24):16828-16842. PubMed ID: 38055861
[TBL] [Abstract][Full Text] [Related]
7. Radiotherapy-Triggered Proteolysis Targeting Chimera Prodrug Activation in Tumors.
Yang C; Yang Y; Li Y; Ni Q; Li J
J Am Chem Soc; 2023 Jan; 145(1):385-391. PubMed ID: 36542856
[TBL] [Abstract][Full Text] [Related]
8. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
9. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
10. Glutathione-responsive PROTAC for targeted degradation of ERĪ± in breast cancer cells.
Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
[TBL] [Abstract][Full Text] [Related]
11. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
12. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues.
Shi S; Du Y; Zou Y; Niu J; Cai Z; Wang X; Qiu F; Ding Y; Yang G; Wu Y; Xu Y; Zhu Q
J Med Chem; 2022 Mar; 65(6):5057-5071. PubMed ID: 35175763
[TBL] [Abstract][Full Text] [Related]
13. Photo-regulated PROTACs: A novel tool for temporal control of targeted protein degradation.
Xu H; Ohoka N; Inoue T; Yokoo H; Demizu Y
Bioorg Med Chem Lett; 2024 Jul; 107():129778. PubMed ID: 38702019
[TBL] [Abstract][Full Text] [Related]
14. Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.
Xu M; Yun Y; Li C; Ruan Y; Muraoka O; Xie W; Sun X
J Mater Chem B; 2024 Mar; 12(13):3240-3248. PubMed ID: 38437473
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of PROTAC cooperative recognition for selective protein degradation.
Gadd MS; Testa A; Lucas X; Chan KH; Chen W; Lamont DJ; Zengerle M; Ciulli A
Nat Chem Biol; 2017 May; 13(5):514-521. PubMed ID: 28288108
[TBL] [Abstract][Full Text] [Related]
16. Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.
Maneiro MA; Forte N; Shchepinova MM; Kounde CS; Chudasama V; Baker JR; Tate EW
ACS Chem Biol; 2020 Jun; 15(6):1306-1312. PubMed ID: 32338867
[TBL] [Abstract][Full Text] [Related]
17. MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53.
Hines J; Lartigue S; Dong H; Qian Y; Crews CM
Cancer Res; 2019 Jan; 79(1):251-262. PubMed ID: 30385614
[TBL] [Abstract][Full Text] [Related]
18. Near-Infrared-Activatable PROTAC Nanocages for Controllable Target Protein Degradation and On-Demand Antitumor Therapy.
He Q; Zhou L; Yu D; Zhu R; Chen Y; Song M; Liu X; Liao Y; Ding T; Fan W; Yu W
J Med Chem; 2023 Aug; 66(15):10458-10472. PubMed ID: 37279091
[TBL] [Abstract][Full Text] [Related]
19. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
[TBL] [Abstract][Full Text] [Related]
20. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]